ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-29: Form 8-K; Period of report 2017-12-29; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2017-12-22: Form 8-K; Period of report 2017-12-22; Description 8.01 Other Events; Details 8.01.
- 2017-12-04: Form 8-K; Period of report 2017-12-04; Description 8.01 Other Events; Details 8.01.
- 2017-11-29: Form 8-K; Period of report 2017-11-29; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-29 | 8-K | 2017-12-29 | 1.02 Termination of a Material Definitive Agreement | 1.02 On December 29, 2017, Zogenix, Inc. (the “Company”) repaid in full the entire $20.1 million of outstanding principal and interest under its Loan and Security Agreement dated as of December 30, 2014 (the “Loan Agreement”) among Oxford Finance LLC and Silicon Valley Bank (collectively, the “Lenders”) and the Company. | d508192d8k.htm |
| 2017-12-22 | 8-K | 2017-12-22 | 8.01 Other Events | 8.01 On December 22, 2017, Zogenix, Inc. (the “Company”) filed a prospectus supplement (“Prospectus Supplement”) to the Company’s effective registration statement on Form S-3 (Registration No. 333-220759) related to the Company’s at the market offering of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), pursuant to the Controlled Equity OfferingSM sales agreement (the “Sales Agreement”) previously entered into on May 10, 2016, by and between the Company and Cantor Fitzgerald & Co. as sales agent (“Cantor”). | d514675d8k.htm |
| 2017-12-04 | 8-K | 2017-12-04 | 8.01 Other Events | 8.01 On December 4, 2017, Zogenix, Inc. (the “Company”) announced new data from its first Phase 3 trial (Study 1) of its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. | d499155d8k.htm |
| 2017-11-29 | 8-K | 2017-11-29 | 8.01 Other Events | 8.01 On November 29, 2017, Zogenix, Inc. (the “Company”) announced that the first child has enrolled in the Phase 3 clinical trial for the Company’s lead investigational therapy, ZX008, as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (“LGS”). | zgnx-20171129x8k.htm |
| 2017-11-22 | 8-K | 2017-11-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 17, 2017, Thierry J.P. Darcis, M.D., the Executive Vice President and General Manager, Europe, of Zogenix, Inc. (the “Company”), announced his intent to resign, effective as of November 22, 2017. | d498947d8k.htm |
| 2017-11-07 | 8-K | 2017-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2017, Zogenix, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2017. | zgnx-20170930x8k.htm |
| 2017-10-03 | 8-K | 2017-10-02 | 8.01 Other Events | 8.01 On October 2, 2017, Zogenix, Inc. (“Zogenix” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 6,700,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). | d443486d8k.htm |
| 2017-10-02 | 8-K | 2017-10-02 | 2.02 Results of Operations and Financial Condition | 2.02 Zogenix, Inc. (the “Company”) estimates that its cash and cash equivalents were approximately $64.7 million as of September 30, 2017. | d459478d8k.htm |
| 2017-09-29 | 8-K | 2017-09-29 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 The slides attached as Exhibit 99.1 to this Current Report contain certain additional information related to the clinical results discussed in Item 8.01 below. 8.01 On September 29, 2017, the Company announced positive top-line results from its first Phase 3 trial (Study 1) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. | d462623d8k.htm |
| 2017-09-22 | 8-K | 2017-09-19 | 1.02 Termination of a Material Definitive Agreement | 1.02 Following the previously announced decision by Zogenix, Inc. (the “Company”) and Endo Ventures Limited (“Endo”) to discontinue the manufacturing and supply of Sumavel DosePro, on September 19, 2017, the Company and Endo entered into a Termination Agreement (the “Termination Agreement”) which terminates the License Agreement dated May 16, 2014, by and between the Company and Endo (the “License Agreement”) and the Manufacturing and Supply Agreement dated May 16, 2014, by and between the Company and Endo (the “Supply Agreement”), as well as certain quality agreements related thereto. | endotermination8-k.htm |
| 2017-08-08 | 8-K | 2017-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2017, Zogenix, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2017. | a8-k6x30x2017er.htm |
| 2017-08-03 | 8-K | 2017-08-01 | 1.02 Termination of a Material Definitive Agreement | 1.02 On August 1, 2017, Zogenix, Inc., a Delaware corporation (the “Company”) and Durect Corporation, a Delaware corporation (“Durect”) entered into a Termination Agreement (the “Termination Agreement”), which terminates the Development and License Agreement dated July 11, 2011, by and between the Company and Durect (as amended, the “Durect Agreement”). | d438376d8k.htm |
| 2017-06-22 | 8-K | 2017-06-22 | 8.01 Other Events | 8.01 On June 22, 2017, Zogenix, Inc. (the “Company”) announced that the U.S. Food & Drug Administration (“FDA”) has granted its investigational drug, ZX008 (low-dose fenfluramine), orphan drug designation for the treatment of Lennox Gastaut Syndrome (“LGS”), a refractory, debilitating childhood-onset epilepsy. | d388818d8k.htm |
| 2017-05-23 | 8-K | 2017-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Stockholders of Zogenix, Inc. (the “Company”) was held on May 23, 2017. | zgnx-2017proxyform8xk.htm |
| 2017-05-04 | 8-K | 2017-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2017, Zogenix, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2017. | a8-k3x31x2017er.htm |
| 2017-04-28 | 8-K | 2017-04-27 | 8.01 Other Events | 8.01 On April 27, 2017, Zogenix, Inc. (the “Company”) announced that the last patient has been randomized into the treatment period of Study 1, the Company’s first Phase 3 clinical trial evaluating ZX008 (low-dose fenfluramine) as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. | d347540d8k.htm |
| 2017-03-09 | 8-K | 2017-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2017, Zogenix, Inc. issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2016. | zgnx-2016q4x8k.htm |
| 2017-03-01 | 8-K | 2017-03-01 | 8.01 Other Events | 8.01 On March 1, 2017, Zogenix, Inc. (the “Company”) announced that the European Commission (“EC”) has designated ZX008 (fenfluramine) as an orphan medicinal product for the treatment of Lennox Gastaut Syndrome (“LGS”), a refractory, debilitating childhood-onset epilepsy. | d356388d8k.htm |
| 2017-01-30 | 8-K | 2017-01-30 | 8.01 Other Events | 8.01 On January 30, 2017, Zogenix, Inc. (the “Company”) announced the recent issuance of U.S. Patent No. 9,549,909 from the U.S. Patent & Trademark Office. | d339212d8k.htm |
| 2017-01-09 | 8-K | 2017-01-09 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 9, 2017, Zogenix, Inc. (the “Company” or “Zogenix”) announced that its preliminary unaudited cash and cash equivalents as of December 31, 2016 were approximately $91.6 million. 7.01 Beginning on January 9, 2017, representatives of Zogenix will be attending meetings with investors, analysts and other parties in connection with the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, California. | d325965d8k.htm |
| 2017-01-05 | 8-K | 2017-01-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 5, 2017, Ann D. Rhoads, the Executive Vice President, Chief Financial Officer, Treasurer and Secretary of Zogenix, Inc. (the “Company”), announced her resignation, effective January 16, 2017. | d289344d8k.htm |